TY - JOUR AU - Wu, Y. L. AU - Planchard, D. AU - Lu, S. AU - Sun, H. AU - Yamamoto, N. AU - Kim, D. W. PY - 2019 DA - 2019// TI - Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdy554 DO - 10.1093/annonc/mdy554 ID - Wu2019 ER - TY - STD TI - National Cancer Institute. Surveillance, epidemiology and end results (SEER) stat fact sheets: lung and bronchus cancer. Available at: http://seer.cancer.gov/statfacts/html/lungb.html (Accessed 30 October 2020). UR - http://seer.cancer.gov/statfacts/html/lungb.html ID - ref2 ER - TY - JOUR AU - Wu, Y. L. AU - Sequist, L. V. AU - Tan, E. H. AU - Geater, S. L. AU - Orlov, S. AU - Zhang, L. PY - 2018 DA - 2018// TI - Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials JO - Clin Lung Cancer VL - 19 UR - https://doi.org/10.1016/j.cllc.2018.03.009 DO - 10.1016/j.cllc.2018.03.009 ID - Wu2018 ER - TY - JOUR AU - Zhang, Y. L. AU - Yuan, J. Q. AU - Wang, K. F. AU - Fu, X. H. AU - Han, X. R. AU - Threapleton, D. PY - 2016 DA - 2016// TI - The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.12587 DO - 10.18632/oncotarget.12587 ID - Zhang2016 ER - TY - JOUR AU - Chan, B. A. AU - Hughes, B. G. PY - 2015 DA - 2015// TI - Targeted therapy for non-small cell lung cancer: current standards and the promise of the future JO - Transl Lung Cancer Res VL - 4 ID - Chan2015 ER - TY - STD TI - National Comprehensive Cancer Network®. NCCN Guidelines. Non-small cell lung cancer. Version 8.2020. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.8.2020 ©National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed 30 October 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org. (October 2019). UR - https://www.nccn.org ID - ref6 ER - TY - JOUR AU - Planchard, D. AU - Popat, S. AU - Kerr, K. AU - Novello, S. AU - Smit, E. F. AU - Faivre-Finn, C. PY - 2018 DA - 2018// TI - Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy275 DO - 10.1093/annonc/mdy275 ID - Planchard2018 ER - TY - JOUR AU - Akamatsu, H. AU - Ninomiya, K. AU - Kenmotsu, H. AU - Morise, M. AU - Daga, H. AU - Goto, Y. PY - 2019 DA - 2019// TI - The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV JO - Int J Clin Oncol VL - 24 UR - https://doi.org/10.1007/s10147-019-01431-z DO - 10.1007/s10147-019-01431-z ID - Akamatsu2019 ER - TY - JOUR AU - Roviello, G. AU - Zanotti, L. AU - Cappelletti, M. R. AU - Gobbi, A. AU - Dester, M. AU - Paganini, G. PY - 2018 DA - 2018// TI - Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? JO - Clin Exp Med VL - 18 UR - https://doi.org/10.1007/s10238-017-0460-7 DO - 10.1007/s10238-017-0460-7 ID - Roviello2018 ER - TY - JOUR AU - Solca, F. AU - Dahl, G. AU - Zoephel, A. AU - Bader, G. AU - Sanderson, M. AU - Klein, C. PY - 2012 DA - 2012// TI - Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker JO - J Pharmacol Exp Ther VL - 343 UR - https://doi.org/10.1124/jpet.112.197756 DO - 10.1124/jpet.112.197756 ID - Solca2012 ER - TY - STD TI - Pharmaceuticals and Medical Devices Agency. Review report: GIOTRIF® (afatinib maleate). Available at: http://www.pmda.go.jp/files/000210320.pdf (Accessed 30 October 2020). UR - http://www.pmda.go.jp/files/000210320.pdf ID - ref11 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. AU - O'Byrne, K. AU - Hirsh, V. AU - Mok, T. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER - TY - JOUR AU - Wu, Y. L. AU - Zhou, C. AU - Hu, C. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - STD TI - Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89. ID - ref14 ER - TY - JOUR AU - Paz-Ares, L. AU - Tan, E. H. AU - O'Byrne, K. AU - Zhang, L. AU - Hirsh, V. AU - Boyer, M. PY - 2017 DA - 2017// TI - Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-lung 7 trial JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdw611 DO - 10.1093/annonc/mdw611 ID - Paz-Ares2017 ER - TY - JOUR AU - Kato, T. AU - Yoshioka, H. AU - Okamoto, I. AU - Yokoyama, A. AU - Hida, T. AU - Seto, T. PY - 2015 DA - 2015// TI - Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3 JO - Cancer Sci VL - 106 UR - https://doi.org/10.1111/cas.12723 DO - 10.1111/cas.12723 ID - Kato2015 ER - TY - JOUR AU - Tanaka, H. AU - Taima, K. AU - Tanaka, Y. AU - Itoga, M. AU - Ishioka, Y. AU - Nakagawa, H. PY - 2018 DA - 2018// TI - A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations JO - Med Oncol VL - 35 UR - https://doi.org/10.1007/s12032-018-1098-3 DO - 10.1007/s12032-018-1098-3 ID - Tanaka2018 ER - TY - JOUR AU - Imai, H. AU - Kaira, K. AU - Suzuki, K. AU - Anzai, M. AU - Tsuda, T. AU - Ishizuka, T. PY - 2018 DA - 2018// TI - A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations JO - Lung Cancer VL - 126 UR - https://doi.org/10.1016/j.lungcan.2018.10.014 DO - 10.1016/j.lungcan.2018.10.014 ID - Imai2018 ER - TY - STD TI - The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer, 7th edition. Kanehara & Co, Tokyo, Japan; 2010. ID - ref19 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - National Cancer Institute. Common terminology criteria for adverse events v4.03. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed 30 October 2020). UR - https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf ID - ref21 ER - TY - JOUR AU - Inoue, Y. AU - Inui, N. AU - Asada, K. AU - Karayama, M. AU - Matsuda, H. AU - Yokomura, K. PY - 2015 DA - 2015// TI - Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2784-x DO - 10.1007/s00280-015-2784-x ID - Inoue2015 ER - TY - JOUR AU - Morikawa, N. AU - Minegishi, Y. AU - Inoue, A. AU - Maemondo, M. AU - Kobayashi, K. AU - Sugawara, S. PY - 2015 DA - 2015// TI - First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan study group studies JO - Expert Opin Pharmacother VL - 16 UR - https://doi.org/10.1517/14656566.2015.1002396 DO - 10.1517/14656566.2015.1002396 ID - Morikawa2015 ER - TY - JOUR AU - Maemondo, M. AU - Minegishi, Y. AU - Inoue, A. AU - Kobayashi, K. AU - Harada, M. AU - Okinaga, S. PY - 2012 DA - 2012// TI - First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study JO - J Thorac Oncol VL - 7 UR - https://doi.org/10.1097/JTO.0b013e318260de8b DO - 10.1097/JTO.0b013e318260de8b ID - Maemondo2012 ER - TY - JOUR AU - Abe, T. AU - Takeda, K. AU - Ohe, Y. AU - Kudoh, S. AU - Ichinose, Y. AU - Okamoto, H. PY - 2015 DA - 2015// TI - Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.55.8627 DO - 10.1200/JCO.2014.55.8627 ID - Abe2015 ER - TY - JOUR AU - Kudoh, S. AU - Takeda, K. AU - Nakagawa, K. AU - Takada, M. AU - Katakami, N. AU - Matsui, K. PY - 2006 DA - 2006// TI - Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904) JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.1044 DO - 10.1200/JCO.2006.06.1044 ID - Kudoh2006 ER - TY - JOUR AU - Quoix, E. AU - Zalcman, G. AU - Oster, J. P. AU - Westeel, V. AU - Pichon, E. AU - Lavole, A. PY - 2011 DA - 2011// TI - Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial JO - Lancet. VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)60780-0 DO - 10.1016/S0140-6736(11)60780-0 ID - Quoix2011 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Sugawara, S. AU - Harada, T. AU - Minegishi, Y. AU - Usui, K. PY - 2014 DA - 2014// TI - Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: North Japan Lung Cancer Group trial 0801 JO - Oncologist. VL - 19 UR - https://doi.org/10.1634/theoncologist.2013-0411 DO - 10.1634/theoncologist.2013-0411 ID - Maemondo2014 ER - TY - JOUR AU - Hohenforst-Schmidt, W. AU - Zarogoulidis, P. AU - Steinheimer, M. AU - Benhassen, N. AU - Tsiouda, T. AU - Baka, S. PY - 2016 DA - 2016// TI - Tyrosine kinase inhibitors for the elderly JO - J Cancer VL - 7 UR - https://doi.org/10.7150/jca.14819 DO - 10.7150/jca.14819 ID - Hohenforst-Schmidt2016 ER - TY - JOUR AU - Tamura, K. AU - Nukiwa, T. AU - Gemma, A. AU - Yamamoto, N. AU - Mizushima, M. AU - Ochai, K. PY - 2019 DA - 2019// TI - Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib JO - Int J Clin Oncol VL - 24 UR - https://doi.org/10.1007/s10147-019-01439-5 DO - 10.1007/s10147-019-01439-5 ID - Tamura2019 ER - TY - JOUR AU - Suh, C. H. AU - Park, H. S. AU - Kim, K. W. AU - Pyo, J. AU - Hatabu, H. AU - Nishino, M. PY - 2018 DA - 2018// TI - Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC JO - Lung Cancer VL - 123 UR - https://doi.org/10.1016/j.lungcan.2018.06.032 DO - 10.1016/j.lungcan.2018.06.032 ID - Suh2018 ER - TY - JOUR AU - Yang, J. C. AU - Sequist, L. V. AU - Zhou, C. AU - Schuler, M. AU - Geater, S. L. AU - Mok, T. PY - 2016 DA - 2016// TI - Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw322 DO - 10.1093/annonc/mdw322 ID - Yang2016 ER - TY - JOUR AU - Halmos, B. AU - Tan, E. H. AU - Soo, R. A. AU - Cadranel, J. AU - Lee, M. K. AU - Foucher, P. PY - 2019 DA - 2019// TI - Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo) JO - Lung Cancer VL - 127 UR - https://doi.org/10.1016/j.lungcan.2018.10.028 DO - 10.1016/j.lungcan.2018.10.028 ID - Halmos2019 ER - TY - STD TI - Schuler M, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019;145(6):1569–79. ID - ref34 ER - TY - JOUR AU - Schnell, D. AU - Buschke, S. AU - Fuchs, H. AU - Gansser, D. AU - Goeldner, R. G. AU - Uttenreuther-Fischer, M. PY - 2014 DA - 2014// TI - Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment JO - Cancer Chemother Pharmacol VL - 74 UR - https://doi.org/10.1007/s00280-014-2484-y DO - 10.1007/s00280-014-2484-y ID - Schnell2014 ER -